2026-01-07 - Analysis Report
Okay, let's break down the provided information for Johnson & Johnson (JNJ).

**0) Report Overview:**

This report analyzes Johnson & Johnson (JNJ) based on historical return data, technical indicators, recent news, analyst opinions, earnings, and financial metrics. We'll compare JNJ's performance to the S&P 500 (VOO) and provide an investment outlook based on the available information.

**1) Return Rate Analysis:**

*   **Ticker:** JNJ (Johnson & Johnson)
*   **Company Overview:** Johnson & Johnson is a multinational corporation that develops and manufactures pharmaceuticals, medical devices, and consumer packaged goods.
*   **JNJ Cumulative Return:** 52.36%
*   **VOO Cumulative Return:** 91.00%
*   **Divergence:**
    *   Current: -38.6
    *   Relative Divergence: 31.4

**Analysis:** JNJ has significantly underperformed the S&P 500 over the analyzed period. The current divergence of -38.6 indicates a substantial difference in cumulative returns. The relative divergence of 31.4 suggests that the current divergence is relatively close to the minimum end of its historical divergence range compared to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha   | Beta  | Cap(B) |
|------------|--------|--------|---------|-------|--------|
| 2016-2018  | 6.0%   | 16.8%  | 3.0%    | 0.7   | 307.1  |
| 2017-2019  | 18.0%  | 16.8%  | 1.0%    | 0.7   | 347.1  |
| 2018-2020  | 19.0%  | 16.8%  | -2.0%   | 0.7   | 374.5  |
| 2019-2021  | 32.0%  | 10.7%  | -12.0%  | 0.6   | 407.1  |
| 2020-2022  | 8.0%   | 13.8%  | 10.0%   | 0.5   | 420.4  |
| 2021-2023  | -18.0% | 13.8%  | -19.0%  | 0.3   | 373.0  |
| 2022-2024  | -30.0% | 13.8%  | -50.0%  | 0.2   | 344.1  |
| 2023-2025  | 30.0%  | 13.8%  | -32.0%  | 0.1   | 492.4  |

**Analysis:**

*   **CAGR:**  Fluctuates significantly. Shows strength in some periods (2019-2021) but negative performance in others (2021-2025).
*   **MDD:** Maximum Drawdown is relatively consistent, indicating moderate risk control.
*   **Alpha:**  Alpha is generally negative, indicating underperformance relative to its benchmark, *especially* in recent periods (2018-2025). The high positive Alpha during 2020-2022 is an exception.
*   **Beta:**  Beta is consistently below 1, indicating lower volatility than the market. This suggests JNJ is less sensitive to overall market movements.
*   **Cap(B):** Market capitalization shows an overall upward trend until recently, suggesting growth followed by a correction.

**2) Recent Stock Price Fluctuations:**

*   **Current Close:** 207.35
*   **Last Market Data:** Price: 204.79, Previous Close: 204.31, Change: 0.23
*   **5-day SMA:** 207.28
*   **20-day SMA:** 206.994
*   **60-day SMA:** 198.7602

**Analysis:** The stock price is currently trading above its 5-day, 20-day, and 60-day Simple Moving Averages (SMAs). This *could* suggest an upward trend, particularly as the 5-day and 20-day SMAs are closely aligned, and both are above the 60-day SMA. The last market data suggests a slight positive change.

**3) Technical Indicators:**

*   **MRI:** 0.8 (Medium Investment)
*   **RSI:** 43.29
*   **PPO:** -0.33
*   **Hybrid Signal:** Cash_0%_Buy 80% of cash (2 shares - Caution - MRI:0.70)
*   **Recent Relative Divergence Change:** 2.6 (+) (short-term increase)
*   **Expected Return (%):** -52.2

**Analysis:**

*   **MRI:**  A Medium Investment recommendation suggests a moderate risk profile.
*   **RSI:**  An RSI of 43.29 is in neutral territory, not indicating overbought or oversold conditions.
*   **PPO:**  A slightly negative PPO suggests that the short-term moving average is slightly below the long-term moving average, implying a mild downtrend.
*   **Hybrid Signal:**  The signal recommends buying 80% of available cash with a caution flag, likely due to the MRI.
*   **Recent Divergence Change:** Indicates a short-term rise in divergence.
*   **Expected Return:**  The significantly negative expected return is a *major red flag*. It suggests that, based on current conditions, long-term investment from this point is projected to underperform the S&P 500.

**4) Recent News & Significant Events:**

*   **Mixed News:** The news headlines present a mixed picture:
    *   A drop despite market gains suggests potential company-specific issues.
    *   Positive lupus drug data provides a potential catalyst.
    *   Analyst comparisons with other drug stocks highlight competitive dynamics.
    *   Acquisition by a representative is a minor event.
    *   Forbes suggests more upside in 2026.
    *   Positive trial results for SLE therapy.

**Analysis:** The news is somewhat contradictory. While there are potential positive catalysts (drug data, Forbes' outlook), the headline about the stock dropping despite market gains is concerning. This highlights the importance of looking beyond the surface and understanding the underlying reasons for the stock's movements.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean = 2.16)
*   **Opinions:** 24
*   **Target Price:** Avg: 210.75 / High: 240.00 / Low: 155.00
*   **Recent Rating Changes:** No changes indicated.

**Analysis:**

*   **Analyst Consensus:** The analyst consensus leans towards a "Buy" rating.
*   **Target Price:** The average target price suggests a slight potential upside from the current price. However, the wide range between the high and low target prices suggests uncertainty among analysts.
*   **Recent Rating Changes:** The absence of recent rating changes suggests that analysts haven't drastically altered their views recently.

**5) Recent Earnings Analysis:**

| Date       | EPS  | Revenue   |
|------------|------|-----------|
| 2025-10-22 | 2.14 | 23.99 B$  |
| 2025-07-24 | 2.3  | 23.74 B$  |
| 2025-04-23 | 4.57 | 21.89 B$  |
| 2024-10-23 | 1.12 | 22.47 B$  |
| 2025-10-22 | 1.12 | 22.47 B$  |

**Analysis:**

*   **Revenue:** Revenue is relatively stable over the past few quarters, but there is significant variation quarter to quarter.
*   **EPS:** EPS fluctuates significantly, with a large spike in 2025-04-23.

The variation in EPS and Revenues suggest a dynamic element in JNJ's earnings.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|----------------|
| 2025-09-30  | $23.99B    | 69.56%          |
| 2025-06-30  | $23.74B    | 67.87%          |
| 2025-03-31  | $21.89B    | 66.40%          |
| 2024-12-31  | $22.52B    | 68.35%          |
| 2024-09-30  | $22.47B    | 69.01%          |

**Capital and Profitability:**

| Quarter      | Equity     | ROE    |
|--------------|------------|--------|
| 2025-09-30  | $79.28B    | 6.50%  |
| 2025-06-30  | $78.47B    | 7.06%  |
| 2025-03-31  | $78.11B    | 14.08% |
| 2024-12-31  | $71.49B    | 4.80%  |
| 2024-09-30  | $70.16B    | 3.84%  |

**Analysis:**

*   **Revenue and Profitability:** Revenue is fairly consistent. Profit margins are also relatively stable and high (above 66%), indicating good cost management and pricing power.
*   **Capital and Profitability:** Equity has been increasing, suggesting the company is retaining earnings and growing its asset base. ROE is volatile, with a large increase in 2025-03-31.

**7) Comprehensive Analysis (Summary):**

*   **Underperformance:** JNJ has significantly underperformed the S&P 500 over the analyzed period, indicating potential company-specific issues or sector headwinds.
*   **Moderate Volatility:** JNJ exhibits lower volatility than the market (Beta < 1).
*   **Mixed Signals:** Technical indicators present a mixed picture. The RSI is neutral, and the PPO suggests a mild downtrend. The Hybrid Signal recommends a cautious buy.
*   **Concerning Outlook:** The expected return of -52.2% is extremely concerning and suggests significant underperformance relative to the market if invested long-term from this point.
*   **Mixed News:** Recent news headlines present both positive (drug trial results) and negative (stock drop despite market gains) developments.
*   **Analyst Optimism:** Analysts have a consensus "Buy" rating and a slightly positive target price.
*   **Stable Financials:** Revenue, profit margins, and equity are relatively stable, indicating a financially sound company.

**Overall Recommendation:**

Based on the provided data, a **HOLD** or **AVOID** recommendation is warranted. The underperformance relative to the S&P 500, negative expected return, and mixed signals from technical indicators raise concerns about the investment outlook for JNJ. While the analyst consensus and stable financials provide some reassurance, the risks outweigh the potential rewards at this time. Investors should carefully consider the potential for underperformance and closely monitor future developments before making any investment decisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.